Sarepta Therapeutics Seeks Traditional Approval for Duchenne Muscular Dystrophy Therapies Following FDA Feedback
核心洞察
Sarepta Therapeutics plans to submit supplemental new drug applications by April 2026 to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional FDA approval for Duchenne muscular dystrophy (搜索) treatment.
The ESSENCE confirmatory study showed numerical trends favoring treatment but missed statistical significance on the primary endpoint, though a COVID-adjusted analysis reached borderline significance (P=0.050).
Real-world evidence demonstrates substantial clinical benefits including 7.5-year delay in nighttime ventilation needs and multi-year delays in loss of ambulation for patients treated with these exon-skipping therapies.
Sarepta Therapeutics announced plans to submit supplemental new drug applications (sNDAs) to the FDA by the end of April 2026, seeking conversion of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) from accelerated to traditional approval for treating Duchenne muscular dystrophy (搜索) (DMD (搜索)). The company received FDA feedback confirming the agency's willingness to review data from the ESSENCE confirmatory study alongside substantial real-world evidence supporting these exon-skipping therapies.
Mixed Results from ESSENCE Confirmatory Study
The global Phase 3 ESSENCE study evaluated both therapies in 225 patients aged 6-13 years with DMD (搜索) amenable to exon 45 or 53 skipping. While topline results showed numerical trends favoring treatment over placebo, the primary endpoint of 4-step ascend velocity at 96 weeks did not reach statistical significance, with a least square means difference of 0.06 steps/second (P=0.309).
However, the study was conducted during the COVID-19 pandemic, which impacted data collection. An updated analysis excluding 23 participants (~10% of the intent-to-treat population) whose baseline measurements occurred during the COVID-19 impact period showed a least square means difference of 0.12 steps/second (P=0.050), reaching borderline statistical significance.
The study reinforced the favorable safety profile of exon-skipping therapies, with adverse events being mostly mild (88%) or moderate (10.9%) and comparable between treatment and placebo groups. No new safety signals emerged during the trial.
Substantial Real-World Evidence Supporting Clinical Benefits
Beyond the ESSENCE study results, Sarepta's phosphorodiamidate morpholino oligomer (PMO) therapies have accumulated extensive real-world evidence over more than a decade of use in over 1,800 patients worldwide, ranging from infants as young as 7 months to adults in their 30s.
Real-world studies demonstrate that VYONDYS 53 treatment is associated with a 7.5-year delay in the need for nighttime ventilation. Similarly, AMONDYS 45 treatment shows statistically significant slowing of lung function decline and potentially meaningful benefits in predicted time to use of a cough assist device.
Across Sarepta's PMO portfolio, real-world evidence indicates multi-year survival benefits, delays in time to loss of ambulation of 3 and 4 years, substantial reduction in risk of reaching a left ventricular ejection fraction below 55%, and significant reduction in emergency room and hospital visits.
FDA's Consideration of Real-World Evidence
"In rare diseases like Duchenne, where progression varies widely and meaningful functional changes unfold over years—not months—incorporating real-world data alongside clinical findings can help us better understand long-term outcomes," said Louise Rodino-Klapac, Ph.D., president of research & development and technical operations at Sarepta. "This is especially true for therapies targeting ultra-rare, genetically defined subgroups, where confirmatory studies are inherently complex."
The FDA's willingness to consider real-world evidence alongside clinical trial data represents a significant development for rare disease therapeutics, where traditional large-scale confirmatory studies face inherent challenges due to small patient populations and the progressive nature of these conditions.
Mechanism of Action and Current Approval Status
Both AMONDYS 45 and VYONDYS 53 utilize Sarepta's proprietary phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology. AMONDYS 45 binds to exon 45 of dystrophin (搜索) pre-mRNA, while VYONDYS 53 targets exon 53, resulting in exclusion of these exons during mRNA processing. This exon skipping allows for production of an internally truncated but functional dystrophin protein in patients with genetic mutations amenable to the respective exon skipping.
Currently, both therapies hold accelerated approval based on increases in dystrophin (搜索) production in skeletal muscle observed in treated patients. The accelerated approval pathway allows earlier access to potentially life-saving treatments while confirmatory studies are completed, with continued approval contingent upon verification of clinical benefit.
The adequacy of the combined ESSENCE study data and real-world evidence to support conversion to traditional approval will be determined through the FDA's review process following the planned sNDA submissions.